TLC to Attend 39th Annual JP Morgan Healthcare Conference
SOUTH SAN FRANCISCO, CA and TAIPEI, Taiwan – January 7, 2021 – TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, has been invited to attend the 39th annual JP Morgan Healthcare Conference, scheduled to take place January 10-14, 2021.
JP Morgan Healthcare Conference has been and is the largest and most information healthcare investment symposium in the industry, with attendance of over 8,000 participants each year. This year, the conference will be conducted entirely virtually over the internet instead of physically taking place at the Westin St. Francis Hotel in San Francisco as per tradition, in an effort to impede the spread of COVID-19.
TLC will be attending the conference for the seventh year in a row at the invitation-only event. Members of TLC’s management team will provide updates on the status of the Company’s innovative product candidates, including TLC599 and TLC590, which are non-opioids with the potential to provide extended relief of osteoarthritis pain and postsurgical pain, respectively.
TLC (NASDAQ: TLC, TWO: 4152) is a clinical-stage, specialty pharmaceutical company dedicated to the research and development of novel nanomedicines that maximize the potential of its proprietary lipid-assembled drug delivery platform (LipAD™), including BioSeizer® sustained release technology and NanoX™ active drug loading technology, which are versatile in the choice of active pharmaceutical ingredients and scalable in manufacturing. TLC has a diverse, wholly owned portfolio of therapeutics targeting areas of unmet medical need in pain management, ophthalmology, oncology, and infectious diseases. TLC is consistently ranked top 5% among all listed companies in Taiwan’s Corporate Governance Evaluations.